Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 3/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.39 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL782348 | 0.82 | AKT1 (0.55) | AKT1CTSLCTSBCTSSABCB1 | |
| SCHEMBL782349 | 0.78 | AKT1 (0.51) | AKT1CTSLCTSBCTSSABCB1 | |
| SCHEMBL8018235 | 0.77 | AKT1 (0.50) | AKT1CTSLCTSBCTSSABCB1 | |
| SCHEMBL7570965 | 0.77 | AKT1 (0.50) | AKT1CTSLCTSBCTSSABCB1 | |
| SCHEMBL30915258 | 0.77 | AKT1 (0.50) | AKT1CTSLCTSBCTSSABCB1 | |
| SCHEMBL23130693 | 0.77 | AKT1 (0.50) | AKT1CTSLCTSBCTSSABCB1 | |
| SCHEMBL7562431 | 0.75 | AKT1 (0.49) | AKT1CTSLCTSBCTSSABCB1 | |
| SCHEMBL20506830 | 0.75 | AKT1 (0.46) | AKT1CTSLCTSBCTSSABCB1 | |
| SCHEMBL19567145 | 0.74 | CTSL (0.55) | AKT1CTSLCTSBCTSSRECQL | |
| SCHEMBL3844227 | 0.74 | MEN1 (0.52) | AKT1CTSLCTSBCTSSMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7015223-B1 | Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2006-03-21 | — | — | US | disclosed |
| US-6906068-B1 | Substituted polycyclic aryl and heteroaryl 1,2,4 - triazinones useful as anticoagulants | PHARMACIA CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| US-20050054643-A1 | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2005-03-10 | — | — | US | disclosed |
| US-20040116430-A1 | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-06-17 | — | — | US | disclosed |
| US-6750342-B1 | INHIBITORS OF SERINE PROTEASES; ANTICOAGULANT | PHARMACIA CORPORATION | 2004-06-15 | — | — | US | disclosed |
| US-6653316-B1 | Coronary artery and cerebrovascular diseases | PHARMACIA CORPORATION | 2003-11-25 | — | — | US | disclosed |
| EP-1178970-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRYMIDINONES USEFUL AS ANTICOAGULANTS | Pharmacia Corporation (US) | 2002-02-13 | — | — | EP | disclosed |
| WO-2001087851-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIMIDINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2000069832-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRYMIDINONES USEFUL AS ANTICOAGULANTS | PHARMACIA CORPORATION (US) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054643-A1 | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade | TFPI, PLAT, SERPINC1 | AKT1 2144/4885CTSL 125/4885CTSB 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.